Levels and Significance of Serum Adiponectin in Patients with Chronic HBV Infection at Different Clinical Stages

To analyze the serum APN levels of patients with chronic HBV infection in different clinical stages and their correlation with clinical laboratory examination indicators. A total of 120 HBV-infected patients are included in this study, including chronic HBV carriers, chronic hepatitis B (CHB) and compensated cirrhosis patients, 40 cases in each group, and 40 medical examinees as healthy controls. Compared with the healthy control group, the APN level in the chronic HBV infection group is significantly increased (p<0.05), and the APN level in the cirrhosis group is significantly increased compared with the other two groups (p<0.05). There is no significant difference between the chronic HBV carrier group and the CHB group. The ratio of people with high APN in the high DNA viral load group is higher (p = 0.002, χ2 = 9.143); the APN level of the liver cirrhosis group is significantly different from the non-cirrhosis group (P = 0.004, χ2 = 8.123). There is no significant correlation between APN level and ALT, AST and other indicators (P>, 0.05). High serum APN may be used as a marker for the diagnosis of HBV-infected liver cirrhosis.

Download Full-text

Studies on Mutual Relationship between Anti-HBx and sFas, IL-10 or IL-12 in Sera of Cases with Chronic Hepatitis B Infection

Infection International ◽

10.1515/ii-2017-0075 ◽

2014 ◽

Vol 3 (2) ◽

pp. 49-53

Author(s):

Ai-kun Ding ◽

Li-wei Guo ◽

Yong-kong Wang ◽

Wei Liu ◽

Cheng Li ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Liver Cirrhosis ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Sandwich Elisa ◽

Hbv Infection ◽

Mutual Relationship ◽

Chronic Hbv Infection ◽

Chronic Hbv

Abstract Objective To study the mutual relationship between anti-HBx and IL-10, IL-12 or soluble Fas (sFas) in sera of patients with chronic HBV infection and to explore the importance of anti-HBx detection as well as its role in the development of chronic HBV infection. Methods Total of 90 cases with chronic HBV infection were randomly selected, including 10 of asymptomatic carriers (ASC), 28 of chronic hepatitis B (CHB), 26 of liver cirrhosis (LC) and 26 patients of hepatocellular carcinoma (HCC). Their clinical data and blood samples were collected, and serum was prepared and stored at -73℃. Anti-HBx was detected with an indirect ELISA established in our earlier research, and levels of IL-10, IL-12 and Fas were determined with commercial double-antibody sandwich ELISA kits. The mutual relationship between anti-HBx and IL-10, IL-12 or sFas in serum were analyzed with the software SPSS 20.0. Results All levels of IL-10, IL-12 and sFas in peripheral blood showed a rising trend with development of chronic HBV infection. The levels of IL-10 in ASC, CHB, LC and HCC groups were 13.93 ± 14.40 ng/L, 39.38 ± 20.77 ng/L, 69.06 ± 46.37 ng/L and 62.82 ± 23.42 ng/L, respectively, levels of IL-12 in the 4 groups were 15.64 ± 23.04 ng/L, 68.50 ± 23.14 ng/L, 76.83 ± 12.82 ng/L and 83.74 ± 24.88 ng/L, respectively, and levels of sFas were 58.17 ± 77.42 ng/L, 179.88 ± 104.36 ng/L, 249.22 ± 107.80 ng/L and 252.98 ± 87.65 ng/L, respectively. Twenty-seven out of 90 patients showed a positive result for anti-HBx detection, including 1 in ASC, 4 in CHB, 12 in LC and 10 in HCC group. The levels of IL-10, IL-12 and sFas were higher in anti-HBx positive group than in negative group. Statistical analysis demonstrated significant differences of IL-10 and IL-12 between the two groups (P < 0.05), but the differences of sFas had no statistical significance (P = 0.094). Conclusions Anti-HBx antibody is not protective, and is closely related to IL-10, IL-12 and sFas. It may be an important serum indicator for aggravation from chronic hepatitis B to liver cirrhosis or hepatocellular carcinoma in patients with chronic HBV infection.

Download Full-text

Screening for chronic hepatitis B and C in migrants from Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam in the Arnhem region, The Netherlands

Epidemiology and Infection ◽

10.1017/s0950268813003415 ◽

2014 ◽

Vol 142 (10) ◽

pp. 2140-2146 ◽

Cited By ~ 23

Author(s):

C. RICHTER ◽

G. TER BEEST ◽

E. H. GISOLF ◽

P. VAN BENTUM ◽

C. WAEGEMAEKERS ◽

...

Keyword(s):

Liver Cirrhosis ◽

Hepatitis B ◽

Risk Groups ◽

Hbv Infection ◽

Chronic Hbv Infection ◽

Increased Risk ◽

Chronic Hbv ◽

First Generation Migrants ◽

Chronic Hcv ◽

Former Soviet Republics

SUMMARYMigrants born in hepatitis B virus (HBV) and hepatitis C virus (HCV) endemic countries are at increased risk of being infected with these viruses. The first symptoms may arise when liver damage has already occurred. The challenge is to identify these infections early, since effective treatment has become available. In 2011 we conducted a screening project in first-generation migrants (FGMs) born in Afghanistan, Iran, Iraq, the former Soviet Republics, and Vietnam and living in Arnhem and Rheden. All participants were offered free blood screening for HBV and HCV. In total 959 participants were tested, with the country of origin known for 927, equating to 28·7% of all registered FGMs from the chosen countries. Nineteen percent (n = 176) had serological signs of past or chronic HBV infection and 2·2% (n = 21) had chronic HBV infection. The highest prevalence of chronic HBV infection was found in the Vietnamese population (9·5%, n = 12). Chronic HCV was found in two persons from the former Soviet Republics and one from Vietnam. Twenty-four percent (n = 5) of the newly identified patients with chronic HBV and one of the three patients with chronic HCV received treatment. Three of the patients, two with HCV and one with HBV, already had liver cirrhosis. The highest (9·5%) HBV prevalence was found in FGMs from Vietnam, indicating a high need for focusing on that particular immigrant population in order to identify more people with silent HBV infection. The fact that three patients already had liver cirrhosis underlines the necessity of early identification of HBV and HCV infection in risk groups.

Download Full-text

HBsAg level as a predictor of disease activity in patients with chronic hepatitis B infection with delta-agent

Infekcionnye bolezni ◽

10.20953/1729-9225-2020-4-149-152 ◽

2020 ◽

Vol 18 (4) ◽

pp. 149-152

Author(s):

M.A. Abdukadyrova ◽

◽

S.M. Sharapov ◽

A.S. Khikmatullaeva ◽

◽

...

Keyword(s):

Liver Cirrhosis ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Disease Activity ◽

Chronic Hepatitis B ◽

Hbv Dna ◽

Hbv Infection ◽

Hbsag Level ◽

Chronic Hbv Infection ◽

Chronic Hbv

We have conducted a pilot study to identify the association between the HBsAg level and activity of the pathological process in the liver, as well as possibility of quantitative assessment of HBsAg for monitoring chronic liver diseases caused by hepatitis B virus (HBV) and hepatitis D virus (HDV). Objective. To assess the possibility of using HBsAg levels as a predictor of disease activity and prognosis in patients with chronic HBV infection with delta-agent. Patients and methods. We analyzed serum specimens from 30 patients with HDV and HBV co-infection. Among 15 patients with chronic hepatitis B with delta-agent, there were 5 HBV DNA positive and 10 HBV DNA negative. Among patients with liver cirrhosis, HBV DNA was detected in 11 individuals, while 4 individuals had undetectable HBV DNA levels. Results. We found that mean HBsAg level in patients with chronic HBV infection and negative HBV DNA was 1.9 ± 0.56 IU/mL. Mean HBsAg level in patients with chronic HBV infection with delta-agent and positive HBV DNA was 4.3 ± 0.62 IU/mL (p < 0.05). High HBsAg levels correlated with elevated ALT in patients with chronic hepatitis B and delta-agent. Patients with liver cirrhosis caused by HDV had normal ALT levels, but elevated bilirubin concentrations regardless of HBV DNA presence and HBsAg level. Conclusion. High levels of HBsAg can be considered as a predictor of active disease in patients with chronic HBV infection with delta-agent and also a marker of transformation of chronic hepatitis B with delta-agent into liver cirrhosis. Key words: chronic hepatitis B with delta agent, liver cirrhosis, enzyme-linked immunosorbent assay, HBsAg levels, polymerase chain reaction

Download Full-text

Correlation Between Liver Cirrhosis and Risk of Cardiac Arrhythmias

Revista de Chimie ◽

10.37358/rc.18.6.6361 ◽

2018 ◽

Vol 69 (6) ◽

pp. 1527-1532

Author(s):

Veronica Calborean ◽

Silvia Alina Miscoci ◽

Octavian Istratoaie ◽

Oana Galceava ◽

Dragos Ovidiu Alexandru ◽

...

Keyword(s):

Atrial Fibrillation ◽

Liver Cirrhosis ◽

Cardiac Arrhythmias ◽

Hcv Infection ◽

Hbv Infection ◽

Alcoholic Liver Cirrhosis ◽

Chronic Hbv Infection ◽

Chronic Hcv Infection ◽

Chronic Hbv ◽

Chronic Hcv

There are few studies analyzing the correlation between liver cirrhosis and cardiac arrhythmias. Still, factors triggering cardiac arrhythmias occur in many instances in liver cirrhosis.We studied a cohort with patientsdiagnosed with liver cirrhosis hospitalized to Cardiology Department, to the County Hospital of Craiova, between January 2017 and January 2018. We wanted to study the frequency of cardiac arrhythmias at the patients diagnosed with liver cirrhosis and also to evaluate several associated factors.The frequency of cardiac arrhythmias in the presence of risk factors was analysed using x2 test and statistical models.We analized multiple variable including demographics and clinical and biochemical characteristics, frequency of type of arrhythmias and evaluation of the associated factors like diabetes mellitus, hypertension, hypercholesterolemia, hypertriglyceridemia ,hyper/hypokalemia and hyper/hyponatremia. From our group, after exclusion criteria, we have a total of 34 patients with alcoholic liver cirrhosis, 37 patients with chronic HCV infection and 36 patients with HBV infection. From 34 patients with alcoholic liver cirrhosis, 23 patients presented atrial fibrillation(67.65%), from 37 patients with chronic HCV infection 21 were diagnosed with atrial fibrillation(56.76%) and from the patients with HBV infection 19 patients were known with atrial fibrillation(52.78%).We have encounter atrial flutter at 2 patients (5.56%) with chronic HBV infection. Atrial extrasystole was found at 7 patients with chronic HBV infection (19.44%), 4 patients with chronic HCV infection (10.81%) and 1 patients with alcoholic liver cirrhosis (2.94%). Ventricular extrasystole was found at 12 patients with chronic HBV infection (33.33%), 3 patients with chronic HCV infection (8.11%) and 5 patients with alcoholic liver cirrhosis (14.71%).We have also correlate the arrhythmias with different biochemical variables from our cohort. In our study there were many association between hepatic cirrhosis and cardiac abnormalities, which is concordant to reports from literature. Compared to population without liver cirrhosis, the prevalence of arrhythmias was increased in our cohort.

Download Full-text

Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection

Medicine ◽

10.1097/md.0000000000021387 ◽

2020 ◽

Vol 99 (33) ◽

pp. e21387

Author(s):

Dexin Wang ◽

Xiuping Yan ◽

Min Zhang ◽

Cuicui Ren ◽

Lili Wang ◽

...

Keyword(s):

Liver Cirrhosis ◽

Glomerular Filtration ◽

Hbv Infection ◽

Chronic Hbv Infection ◽

Chronic Hbv ◽

Estimated Glomerular Filtration Rates

Download Full-text

Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study

Technology in Cancer Research & Treatment ◽

10.1177/1533033820980785 ◽

2020 ◽

Vol 19 ◽

pp. 153303382098078

Author(s):

Rongming Wang ◽

Weiwei Zang ◽

Bobin Hu ◽

Deli Deng ◽

Xiaozhang Ling ◽

...

Keyword(s):

Hepatitis B ◽

Hbv Infection ◽

Healthy Control Group ◽

Control Group ◽

High Risk Population ◽

Chronic Hbv Infection ◽

S Gene ◽

Healthy Control ◽

Chronic Hbv ◽

Gene Integration

Aims: To investigate the feasibility of serum extra spindle pole bodies-like 1 (ESPL1) used as a biomarker for patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: 131 chronic HBV-infection patients were recruited and divided into HBV S gene integration, non-HBV S gene integration, chronic hepatitis B (CHB), HBV-related liver cirrhosis (LC) and HBV-related HCC group, 24 non-HBV-related HCC patients were selected as HCC control group, 30 people without HBV-infection as healthy control group. Serum ESPL1 were detected and compared. Results: ESPL1 level of integration group was significantly higher than that of non-integration group (346.7 vs 199.6 ng/ml, P = 0.000) and healthy control group (346.7 vs 41.3 ng/ml, P = 0.000). ESPL1 level of non-integration group was significantly higher than that of healthy control group (199.6 vs 41.3 ng/ml, P = 0.000); ESPL1 levels in chronic HBV-infection related groups were increased in turn according to CHB group (95.8 ng/ml), HBV-related LC group (268.2 ng/ml), HBV-related HCC group (279.9 ng/ml) and integration group (346.7 ng/ml). Except that there was no significant difference in ESPL1 levels between HBV-related LC and HCC group ( P = 0.662), pairwise comparisons between other groups showed significant differences ( P < 0.05). ESPL1 level of HBV-related HCC group was significantly higher than that of non-HBV-related HCC group (279.9 vs 46.6 ng/ml, P = 0.000), there was no noticeable difference between non-HBV-related HCC and healthy control group (46.6 vs 41.3 ng/ml, P = 0.848). ESPL1 level of HBV-related HCC group after resection was significantly lower than that of before resection (178.4 vs 260.8 ng/ml, P = 0.000). Conclusions: Chronic HBV-infection patients with high ESPL1 level may indicate HBV S gene integration and is a high-risk population for HBV-related HCC. Serum ESPL1 can be used as a biomarker for screening HBV-related HCC high-risk population and monitoring recurrence.

Download Full-text

Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load

World Journal of Gastroenterology ◽

10.3748/wjg.15.3382 ◽

2009 ◽

Vol 15 (27) ◽

pp. 3382 ◽

Cited By ~ 6

Author(s):

Jing You ◽

Lin Zhuang ◽

Yi-Feng Zhang ◽

Hong-Ying Chen ◽

Hutcha Sriplung ◽

...

Keyword(s):

T Lymphocyte ◽

Lymphocyte Subpopulations ◽

Hbv Infection ◽

Chronic Hbv Infection ◽

T Lymphocyte Subpopulations ◽

Clinical Stages ◽

Chronic Hbv

Download Full-text

miR-98-5p as a Novel Biomarker Suppress Liver Fibrosis by Targeting TGFβ Receptor 1

10.21203/rs.3.rs-520986/v1 ◽

2021 ◽

Author(s):

Yanhua Ma ◽

xiaoxue yuan ◽

Ming Han ◽

Kai Han ◽

Pu Liang ◽

...

Keyword(s):

Liver Fibrosis ◽

Signaling Pathway ◽

Target Genes ◽

Enrichment Analysis ◽

Hbv Infection ◽

Differentially Expressed ◽

Control Group ◽

Chronic Hbv Infection ◽

Differentially Expressed Mirnas ◽

Chronic Hbv

Abstract Hepatic fibrosis is the repair reaction of excessive deposition and abnormal distribution of extracellular matrix after various liver injuries, especially chronic HBV infection, which is a key step in the development of various chronic liver diseases to cirrhosis. Recent studies show that microRNAs (miRNA) can regulate a series of liver fibrosis-related gene express and play an important role in the development of liver fibrosis. To detect the miRNAs expression profiling and to screen the differentially expressed miRNAs in patients with HBV-related liver fibrosis, the whole blood was collected from the HBV-related liver fibrosis patients (F2/3, n=10) based on Scheuer’s staging criteria. In addition, healthy volunteers (n=8) served as the control group. The expression of plasma miRNAs was detected by IlluminaHiSeq sequencing. Cluster analysis and target genes prediction of differentially expressed miRNAs were carried out. Gene ontology (GO) enrichment analysis and KEGG pathway enrichment analysis of differentially expressed miRNAs target genes were performed. Compared with the healthy control group 104 miRNAs were screened out from the liver fibrosis group, among which 72 miRNAs were up-regulated and 32 were down-regulated. Pathway annotations for the target genes of the miRNAs identified were found that it participated in many signal pathways including MAPK signaling pathway, TNF signaling pathway, Notch signaling pathway, phosphatidylinositol signal system and so on. According to the bioinformatic analysis，miR-98-5p were selected for function research among the differentially expressed miRNAs.MiR-98-5p prevents liver fibrosis by targeting TGFβR1 and blocking TGFβ1/Smad3 signaling pathway. In addition, serum miR-98-5p levels were measured from a total of 70 recruited patients with chronic HBV infection and 29 healthy individuals as controls. We found that serum miR-98-5p level was significantly lower in patients with live fibrosis than in healthy controls and HBV carriers (P<0.05). Those results suggest that miR-98-5p could be a potential therapeutic target for liver fibrosis .

Download Full-text